ChromoCure's aneuploidy theory of cancer further validated

ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announces that its long-held theory of cancer, aneuploidy, has been further validated by a study published in the January 15, 2010 issue of Cancer Research (Volume 70, Issue 2). Authors Cui, Borysova, Johnson and Guadagno, affiliated (respectively) with the Department of Molecular Oncology and Analytic Microscopy Core Facility, H. Lee Moffitt Cancer Center and Research Institute and Cancer Biology Graduate Program, University of South Florida, Tampa, Florida, concluded that "Evidence is offered for the hypothesis that the early, founding effects of B-Raf mutations on melanoma development occur initially through aneuploidy, before the benefits of activated B-Raf to transformed cell growth and survival can accrue."

These findings, together with recently announced supporting studies at the Mayo Clinic, have further validated the chromosomal theory of cancer, a theory long championed by ChromoCure. Their findings, which appear in the December 2009 issue of the journal Cancer Cell along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

These ground breaking research publications have initiated renewed interest in aneuploidy research and reinforced ChromoCure's leading edge status. As recently announced, ChromoCure has accelerated the implementation of the Therapy and Cure component of ChromoCure's business plan and is reshaping other segments of its Business Plan.

The company welcomes these corroborating research publications and anticipates the announcement of important new initiatives.